PMID- 32000639
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201104
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 26
IP  - 10
DP  - 2020
TI  - Dysmetabolic Iron Overload in Metabolic Syndrome.
PG  - 1019-1024
LID - 10.2174/1381612826666200130090703 [doi]
AB  - BACKGROUND: We sought to determine the association of dysmetabolic iron overload 
      syndrome (DIOS) with metabolic syndrome (MetS). METHODS: Several studies have 
      shown that DIOS is associated with Mets, mainly through the pathogenesis of its 
      components: type 2 diabetes mellitus (T2DM), essential hypertension, 
      non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (POS). 
      RESULTS: Serum ferritin levels increase proportionally according to the degree of 
      insulin resistance (IR) and the number of components of Mets. Moreover, DIOS 
      predicts the onset of T2DM and NAFLD. Dysregulation of iron metabolism in DIOS is 
      due to a multifactorial and dynamic process triggered by an unhealthy diet, 
      facilitated by environmental and genetic cofactors, and resulting in a 
      bidirectional relation between the liver and visceral adipose tissue (VAT). Iron 
      removal combined with a healthy diet improved both insulin sensitivity and 
      beta-cell function, but had no significant effect on blood glucose; however, 
      phlebotomy therapy might be considered with conflicting results. CONCLUSION: Iron 
      overload is closely associated with metabolic syndrome and its components; 
      however, it remains under-appreciated in everyday clinical practice. Diet and 
      lifestyle modification offer some clinical benefit; however, it is not adequate 
      for successful management of the disease. The results of phlebotomy remain 
      controversial, underlying the necessity of further efforts in this field.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Sachinidis, Alexandros
AU  - Sachinidis A
AD  - 2nd Propaedeutics Department of Internal Medicine, Hippocration Hospital, Medical 
      School of Aristotle University Thessaloniki, Greece.
FAU - Doumas, Michael
AU  - Doumas M
AD  - 2nd Propaedeutics Department of Internal Medicine, Hippocration Hospital, Medical 
      School of Aristotle University Thessaloniki, Greece.
AD  - Georgetown University and VAMC and George Washington University, Washington DC, 
      United States.
FAU - Imprialos, Konstantinos
AU  - Imprialos K
AD  - 2nd Propaedeutics Department of Internal Medicine, Hippocration Hospital, Medical 
      School of Aristotle University Thessaloniki, Greece.
AD  - Georgetown University and VAMC and George Washington University, Washington DC, 
      United States.
FAU - Stavropoulos, Konstantinos
AU  - Stavropoulos K
AD  - 2nd Propaedeutics Department of Internal Medicine, Hippocration Hospital, Medical 
      School of Aristotle University Thessaloniki, Greece.
FAU - Katsimardou, Alexandra
AU  - Katsimardou A
AD  - 2nd Propaedeutics Department of Internal Medicine, Hippocration Hospital, Medical 
      School of Aristotle University Thessaloniki, Greece.
FAU - Athyros, Vasilios G
AU  - Athyros VG
AD  - 2nd Propaedeutics Department of Internal Medicine, Hippocration Hospital, Medical 
      School of Aristotle University Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 9007-73-2 (Ferritins)
RN  - E1UOL152H7 (Iron)
SB  - IM
MH  - Diabetes Mellitus, Type 2
MH  - Diet/adverse effects
MH  - Essential Hypertension
MH  - Female
MH  - Ferritins/blood
MH  - Humans
MH  - Insulin Resistance
MH  - Iron
MH  - Iron Overload/*complications
MH  - Life Style
MH  - Metabolic Syndrome/*complications
MH  - Non-alcoholic Fatty Liver Disease
MH  - Phlebotomy
MH  - Polycystic Ovary Syndrome
OTO - NOTNLM
OT  - Serum ferritin
OT  - arterial hypertension
OT  - dysmetabolic iron overload syndrome
OT  - insuline resistance
OT  - metabolic syndrome
OT  - type two diabetes.
EDAT- 2020/02/01 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/02/01 06:00
PHST- 2019/08/23 00:00 [received]
PHST- 2019/12/16 00:00 [accepted]
PHST- 2020/02/01 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
PHST- 2020/02/01 06:00 [entrez]
AID - CPD-EPUB-104075 [pii]
AID - 10.2174/1381612826666200130090703 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2020;26(10):1019-1024. doi: 10.2174/1381612826666200130090703.